Regulus Therapeutics reported $4.41M in Debt for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Debt Change
Alnylam Pharmaceuticals ALNY:US $ 676.71M 1.01M
Astrazeneca AZN:US $ 31099M 318M
AstraZeneca AZN:LN 31099M 318M
Biogen BIIB:US $ 7275.2M 2.1M
Celldex Therapeutics CLDX:US $ 0M 0M
Gilead Sciences GILD:US $ 26208M 487M
GlaxoSmithKline GSK:LN 33328M 9155M
Intercept Pharmaceuticals ICPT:US $ 716.88M 177.1M
Intrexon XON:US $ 201.47M 18.32M
Lexicon Pharmaceuticals LXRX:US $ 23.48M 23.48M
Ligand Pharmaceuticals LGND:US $ 176.59M 144.17M
Merk MRK:US $ 31794M 1308M
Omeros OMER:US $ 313.9M 517K
Regulus Therapeutics RGLS:US $ 4.41M 0.26M
Sangamo Biosciences SGMO:US $ 0M 0M
Spectrum Pharmaceuticals SPPI:US $ 0M 0M
Takeda 4502:JP Y 4345411M 9464M
Vital Therapies VTL:US $ 0M 0M
YTE INCY:US $ 34.18M 0.09M